|
1
|
He H, Ni J and Huang J: Molecular
mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett.
7:1352–1362. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ducreux M, Petersen LN, Ohler L, Bergamo
F, Metges JP, de Groot JW, Wang JY, García Paredes B, Dochy E,
Fiala-Buskies S, et al: Safety and effectiveness of regorafenib in
patients with metastatic colorectal cancer in routine clinical
practice in the prospective, observational CORRELATE study. Eur J
Cancer. 123:146–154. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Morrow JJ and Khanna C: Osteosarcoma
genetics and epigenetics: Emerging biology and candidate therapies.
Crit Rev Oncog. 20:173–197. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun K, Gong C, Peng H, Fang H, Zhou J, Li
J, Chen S and Zheng H: High CCL5 expression is associated with
osteosarcoma metastasis and poor prognosis of patients with
osteosarcoma. Mol Med Rep. 16:6953–6957. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
He F, Zhang W, Shen Y, Yu P, Bao Q, Wen J,
Hu C and Qiu S: Effects of resection margins on local recurrence of
osteosarcoma in extremity and pelvis: Systematic review and
meta-analysis. Int J Surg. 36:283–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Buljan M, Blattmann P, Aebersold R and
Boutros M: Systematic characterization of pan-cancer mutation
clusters. Mol Syst Biol. 14:e79742018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heffernan-Stroud LA and Obeid LM:
Sphingosine kinase 1 in cancer. Adv Cancer Res. 117:201–235. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schiefler C, Piontek G, Doescher J,
Schuettler D, Mißlbeck M, Rudelius M, Haug A, Reiter R, Brockhoff G
and Pickhard A: Inhibition of SphK1 reduces radiation-induced
migration and enhances sensitivity to cetuximab treatment by
affecting the EGFR/SphK1 crosstalk. Oncotarget. 5:9877–9888. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang S, Liang Y, Chang W, Hu B and Zhang
Y: Triple negative breast cancer depends on Sphingosine Kinase 1
(SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-phosphate
receptor 3 (S1PR3)/notch signaling for metastasis. Med Sci Monit.
24:1912–1923. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hatoum D, Haddadi N, Lin Y, Nassif NT and
McGowan EM: Mammalian sphingosine kinase (SphK) isoenzymes and
isoform expression: Challenges for SphK as an oncotarget.
Oncotarget. 8:36898–36929. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen J, Qi Y, Zhao Y, Kaczorowski D,
Couttas TA, Coleman PR, Don AS, Bertolino P, Gamble JR, Vadas MA,
et al: Deletion of sphingosine kinase 1 inhibits liver
tumorigenesis in diethylnitrosamine-treated mice. Oncotarget.
9:15635–15649. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang F and Wu Z: Sphingosine kinase 1
overexpression is associated with poor prognosis and oxaliplatin
resistance in hepatocellular carcinoma. Exp Ther Med. 15:5371–5376.
2018.PubMed/NCBI
|
|
13
|
Zhao Z, Ma J, Hu B, Zhang Y and Wang S:
SPHK1 promotes metastasis of thyroid carcinoma through activation
of the S1P/S1PR3/Notch signaling pathway. Exp Ther Med.
15:5007–5016. 2018.PubMed/NCBI
|
|
14
|
Madhunapantula SV, Hengst J, Gowda R, Fox
TE, Yun JK and Robertson GP: Targeting sphingosine kinase-1 to
inhibit melanoma. Pigment Cell Melanoma Res. 25:259–274. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gault CR and Obeid LM: Still benched on
its way to the bedside: Sphingosine kinase 1 as an emerging target
in cancer chemotherapy. Crit Rev Biochem Mol Biol. 46:342–351.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun K, Zhang Y, D'Alessandro A, Nemkov T,
Song A, Wu H, Liu H, Adebiyi M, Huang A, Wen YE, et al:
Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen
release for adaptation to high-altitude hypoxia. Nat Commun.
7:120862016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cuvillier O, Ader I, Bouquerel P, Brizuela
L, Gstalder C and Malavaud B: Hypoxia, therapeutic resistance, and
sphingosine 1-phosphate. Adv Cancer Res. 117:117–141. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xiong H, Wang J, Guan H, Wu J, Xu R, Wang
M, Rong X, Huang K, Huang J, Liao Q, et al: SphK1 confers
resistance to apoptosis in gastric cancer cells by downregulating
Bim via stimulating Akt/FoxO3a signaling. Oncol Rep. 32:1369–1373.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bao Y, Guo Y, Zhang C, Fan F and Yang W:
Sphingosine Kinase 1 and Sphingosine-1-phosphate signaling in
colorectal cancer. Int J Mol Sci. 18:21092017. View Article : Google Scholar
|
|
20
|
Li W, Li J, Wang Y, Zhang K, Li N, Tian Z,
Ni B, Wang H and Ruan Z: Sphingosine kinase 1 is a potential
therapeutic target for nasopharyngeal carcinoma. Oncotarget.
7:80586–80598. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu PH, Chen MB, Liu YY, Wu MH, Li WT, Wei
MX, Liu CY and Qin SK: Identification of sphingosine kinase 1
(SphK1) as a primary target of icaritin in hepatocellular carcinoma
cells. Oncotarget. 8:22800–22810. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yao C, Wu S, Li D, Ding H, Wang Z, Yang Y,
Yan S and Gu Z: Co-administration phenoxodiol with doxorubicin
synergistically inhibit the activity of sphingosine kinase-1
(SphK1), a potential oncogene of osteosarcoma, to suppress
osteosarcoma cell growth both in vivo and in vitro. Mol Oncol.
6:392–404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C (T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nazouri AS, Asadpour O, Dabiri S,
Pourseyedi B, Lashkarizadeh MR and Zianalinejad H: High expression
of sphingosine kinase 1 in estrogen and progesterone
receptors-negative breast cancer. Iran J Pathol. 12:218–224. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bonhoure E, Pchejetski D, Aouali N,
Morjani H, Levade T, Kohama T and Cuvillier O: Overcoming
MDR-associated chemoresistance in HL-60 acute myeloid leukemia
cells by targeting sphingosine kinase-1. Leukemia. 20:95–102. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Katsuta E, Yan L, Nagahashi M, Raza A,
Sturgill JL, Lyon DE, Rashid OM, Hait NC and Takabe K: Doxorubicin
effect is enhanced by sphingosine-1-phosphate signaling antagonist
in breast cancer. J Surg Res. 219:202–213. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu C, Zhang W, Liu S, Wu W, Qin M and
Huang J: Activation of the SphK1/ERK/p-ERK pathway promotes
autophagy in colon cancer cells. Oncol Lett. 15:9719–9724.
2018.PubMed/NCBI
|
|
28
|
Matula K, Collie-Duguid E, Murray G,
Parikh K, Grabsch H, Tan P, Lalwani S, Garau R, Ong Y, Bain G, et
al: Regulation of cellular sphingosine-1-phosphate by sphingosine
kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy
resistance in gastroesophageal cancer. BMC Cancer. 15:7622015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Meng Y, Gao R, Ma J, Zhao J, Xu E, Wang C
and Zhou X: MicroRNA-140-5p regulates osteosarcoma chemoresistance
by targeting HMGN5 and autophagy. Sci Rep. 7:4162017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim M, Jung JY, Choi S, Lee H, Morales LD,
Koh JT, Kim SH, Choi YD, Choi C, Slaga TJ, et al: GFRA1 promotes
cisplatin-induced chemoresistance in osteosarcoma by inducing
autophagy. Autophagy. 13:149–168. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bernacchioni C, Ghini V, Cencetti F,
Japtok L, Donati C, Bruni P and Turano P: NMR metabolomics
highlights sphingosine kinase-1 as a new molecular switch in the
orchestration of aberrant metabolic phenotype in cancer cells. Mol
Oncol. 11:517–533. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Watson DG, Tonelli F, Alossaimi M,
Williamson L, Chan E, Gorshkova I, Berdyshev E, Bittman R, Pyne NJ
and Pyne S: The roles of sphingosine kinases 1 and 2 in regulating
the Warburg effect in prostate cancer cells. Cell Signal.
25:1011–1017. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ma Q, Zhang Y, Liu T, Jiang K, Wen Y, Fan
Q and Qiu X: Hypoxia promotes chemotherapy resistance by
down-regulating SKA1 gene expression in human osteosarcoma. Cancer
Biol Ther. 18:177–185. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sowa T, Menju T, Chen-Yoshikawa TF,
Takahashi K, Nishikawa S, Nakanishi T, Shikuma K, Motoyama H,
Hijiya K, Aoyama A, et al: Hypoxia-inducible factor 1 promotes
chemoresistance of lung cancer by inducing carbonic anhydrase IX
expression. Cancer Med. 6:288–297. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Badowska-Kozakiewicz AM, Sobol M and
Patera J: Expression of multidrug resistance protein P-glycoprotein
in correlation with markers of hypoxia (HIF-1α, EPO, EPO-R) in
invasive breast cancer with metastasis to lymph nodes. Arch Med
Sci. 13:1303–1314. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xie Y and Zhong DW: AEG-1 is associated
with hypoxia-induced hepatocellular carcinoma chemoresistance via
regulating PI3K/AKT/HIF-1alpha/MDR-1 pathway. Excli J. 15:745–757.
2016.PubMed/NCBI
|
|
37
|
Doublier S, Belisario DC, Polimeni M,
Annaratone L, Riganti C, Allia E, Ghigo D, Bosia A and Sapino A:
HIF-1 activation induces doxorubicin resistance in MCF7 3-D
spheroids via P-glycoprotein expression: A potential model of the
chemo-resistance of invasive micropapillary carcinom of the breast.
BMC Cance. 12:42012. View Article : Google Scholar
|
|
38
|
Cao Y, Eble JM, Moon E, Yuan H, Weitzel
DH, Landon CD, Nien CY, Hanna G, Rich JN, Provenzale JM and
Dewhirst MW: Tumor cells upregulate normoxic HIF-1α in response to
doxorubicin. Cancer Res. 73:6230–6242. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ader I, Brizuela L, Bouquerel P, Malavaud
B and Cuvillier O: Sphingosine kinase 1: A new modulator of hypoxia
inducible factor 1alpha during hypoxia in human cancer cells.
Cancer Res. 68:8635–8642. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sevelda F, Mayr L, Kubista B, Lötsch D,
van Schoonhoven S, Windhager R, Pirker C, Micksche M and Berger W:
EGFR is not a major driver for osteosarcoma cell growth in vitro
but contributes to starvation and chemotherapy resistance. J Exp
Clin Cancer Res. 34:1342015. View Article : Google Scholar : PubMed/NCBI
|
